Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. India
  4. NSE India Stock Exchange
  5. Larsen & Toubro Infotech Limited
  6. News
  7. Summary
    LTI   INE214T01019


SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Larsen & Toubro Infotech : LTI and eClinicalHealth Form Strategic Partnership to Accelerate Innovation in Clinical Research

09/28/2021 | 10:01am EST

MUMBAI, India, Sept. 28, 2021 /CNW/ -- Larsen & Toubro Infotech (BSE: 540005) (NSE: LTI), a global technology consulting and digital solutions company has entered in a strategic partnership with eClinicalHealth Limited to accelerate digital innovation in R&D Clinical Trials Management process for patient-centric drug development. The partnership will help clients decentralize clinical trials setting new benchmarks of excellence in clinical research space.

LTI Logo

The significance of the tie-up is based on the fact that 86 percent of clinical studies are delayed* due to challenges in patient engagement – mainly involving recruitment and retaining patients, which is a time consuming and expensive process. The pandemic has further aggravated this challenge. It is in this context that eClinicalHealth, which is focused on developing innovative clinical trial solutions, launched cloud-based patient-centric SaaS solution, Clinpal – which improves patient engagement for each clinical trial journey.  

As part of this strategic partnership, LTI with its digital, technical and life sciences domain capabilities, will help accelerate joint go-to-market pursuits and faster deployment for Clinpal Adopters. The solution will make use of exponential technologies such as analytics and AI to enhance patient engagement and faster clinical studies.

Archana Ramanakumar, EVP & Global Delivery Head – Life Sciences, Media, Consumer & Technology, LTI commented: "At LTI, we are on a journey to drive digital transformation for various aspects of clinical trials. Our endeavour with eClinicalHealth partnership is to accelerate and streamline the enablement of Decentralized Trials, to reduce patient burden and drive acceleration of clinical trials. With this partnership we aim to accelerate the development and deployment of eClinicalHealth's ClinPal platform in clinical trials for the industry."

Karl Landert, Chairman of the Board and CEO at eClinicalHealth said: "The new normal world has put into limelight the benefits of a telemedicine ecosystem for larger benefit of end-users. Clinical trials assume an important function in development and improvement of treatment methods in order to enhance patient's wellbeing, and De-Centralized Trials (DCT) have attained highest order of patient preference. With our strategic partnership with LTI, our aim is to further scale and simplify patient engagement."

*Contemporary Clinical Trials Volume 66, March 2018, https://doi.org/10.1016/j.cct.2018.01.003

About LTI:

LTI (NSE: LTI) is a global technology consulting and digital solutions Company helping more than 435 clients succeed in a converging world. With operations in 31 countries, we go the extra mile for our clients and accelerate their digital transformation with LTI's Mosaic platform enabling their mobile, social, analytics, IoT and cloud journeys. Founded in 1997 as a subsidiary of Larsen & Toubro Limited, our unique heritage gives us unrivalled real-world expertise to solve the most complex challenges of enterprises across all industries. Each day, our team of more than 36,000 LTItes enable our clients to improve the effectiveness of their business and technology operations and deliver value to their customers, employees and shareholders. Find more at http://www.Lntinfotech.com or follow us at @LTI_Global.

About eClinicalHealth:

Headquartered in Scotland, eClinicalHealth Limited, developers of the revolutionary Clinpal patient engagement platform, was founded in early 2012 to provide innovative clinical trial solutions. The company is committed to leading open and collaborative innovation discussions about patient-centric clinical trial processes and technology with pharmaceutical companies, CROs, and other service and technology providers.

Connect with LTI:

  • Read our News and Blogs
  • Follow us on Twitter and LinkedIn
  • Like us on Facebook

View original content:https://www.prnewswire.com/news-releases/lti-and-eclinicalhealth-form-strategic-partnership-to-accelerate-innovation-in-clinical-research-301386294.html


© Canada Newswire, source Canada Newswire English

Stocks mentioned in the article
ChangeLast1st jan.
LARSEN & TOUBRO INFOTECH LIMITED 0.99% 6813.4 Delayed Quote.84.41%
LARSEN & TOUBRO LIMITED -0.55% 1767.6 End-of-day quote.37.28%
11/25Larsen & Toubro Infotech Opens New Innovation Center in Bengaluru, India
11/25Larsen & Toubro Infotech Limited Opens an Innovation & Experience Centre At LTI Whitefi..
11/24LTI Enables Large Scale Digital Transformation for PIH Group of Companies
11/24Indian shares end lower as IT, auto drag
11/24Indian shares end lower as IT, auto drag
11/24Larsen & Toubro Infotech Limited Enables Large Scale Digital Transformation for PIH Gro..
11/09Majesco Partners with Larsen & Toubro Infotech to Transform Business Operations for Ins..
10/27LTI Becomes Microsoft Azure Expert Managed Services Provider
10/27Indian shares mostly flat; big earnings in focus
10/27Indian shares edge higher on consumer, IT gains
More news
Sales 2022 155 B 2 061 M 2 061 M
Net income 2022 23 038 M 307 M 307 M
Net cash 2022 29 020 M 386 M 386 M
P/E ratio 2022 51,5x
Yield 2022 0,73%
Capitalization 1 182 B 15 741 M 15 740 M
EV / Sales 2022 7,45x
EV / Sales 2023 6,15x
Nbr of Employees 42 382
Free-Float 25,4%
Duration : Period :
Larsen & Toubro Infotech Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends LARSEN & TOUBRO INFOTECH LIMITED
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus HOLD
Number of Analysts 29
Last Close Price 6 748,55 INR
Average target price 6 175,52 INR
Spread / Average Target -8,49%
EPS Revisions
Managers and Directors
Sanjay Jalona Chief Executive Officer, MD & Director
Anil Rander Chief Financial Officer
Anil Kumar Manibhai Naik Non-Executive Chairman
Nachiket Deshpande Chief Operating Officer & Director
Angna Arora Director-Corporate Secretary & Compliance Officer
Sector and Competitors